MOTS-c

Known safety concerns, contraindications, and risk factors.

MOTS-c is classified as an FDA Category 2 bulk drug substance. It is prohibited from compounding for human use. The information presented here is for educational and research purposes only. No clinical data supports human use beyond one month. Consult a qualified healthcare provider before considering any peptide therapy.

Immediate Effects (5)

Long-Term Risks (4)

Sourcing Dangers (2)

Contraindications (6)

History of Cancer

Due to conflicting data on growth-factor activity, individuals with a history of prostate, breast, or other malignancies should avoid MOTS-c until definitive safety data is available.

Monitor

Anti-Diabetic Medications

Theoretical synergistic or adverse interactions with Metformin and other AMPK-activating drugs may cause unpredictable glucose metabolism shifts.

Monitor

Competitive Athletes

MOTS-c is banned by WADA under S2 (Peptide Hormones and Growth Factors). Use constitutes a doping violation.

Monitor

Active Autoimmune Disease

While MOTS-c shows immunoregulatory potential, its effects on active autoimmune conditions are unpredictable. The immunogenicity risk further complicates use in immunologically sensitised individuals.

Monitor

Pregnancy and Lactation

No reproductive toxicity data exists. MOTS-c should not be used during pregnancy or breastfeeding.

Monitor

Sex-Dependent Response Variability

Evidence suggests sexual dimorphism in MOTS-c regulation — males show greater metabolic disruption when levels are low compared to pre-menopausal females. Dosing and efficacy may vary significantly between sexes.

Monitor

Auto-Generated Safety Flags

[TRIGGER: DRUG INTERACTION] Metformin — synergistic or adverse interactions with AMPK-activating drugs may cause unpredictable glucose metabolism shifts.

[TRIGGER: MALIGNANCY] History of Cancer — high risk in individuals with prostate or breast cancer histories; MOTS-c may act as a growth factor promoting existing malignancies.

[TRIGGER: REGULATORY] FDA Category 2 — classified as posing 'significant safety risks' with no human exposure data and potential immunogenicity.

[TRIGGER: IMMUNOGENICITY] Anti-Drug Antibodies — significant risk for immunogenicity potentially leading to neutralising antibodies or systemic immune responses.

[TRIGGER: DOPING] WADA S2 — strictly banned under Peptide Hormones and Growth Factors category.

[TRIGGER: CARDIOVASCULAR] Sympathetic Overdrive — documented anecdotal reports of heart palpitations, increased heart rate, and insomnia.

[TRIGGER: PURITY] Grey Market Contamination — products may have purity as low as 60%, containing unknown manufacturing byproducts.

[TRIGGER: INSTABILITY] Half-Life — circulating half-life of only 1–2 hours with 85–90% activity loss at room temperature in 2–3 hours.

[TRIGGER: SYSTEMIC] Constitutional Symptoms — potential for fever, nausea, vomiting, and persistent injection site bumps.

Continue